Navigation Links
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Date:4/30/2008

iously received radiotherapy.

This clinical trial has two components. The first is an open-label, dose-escalating, non-randomized study of REOLYSIN(R) given intravenously with paclitaxel and carboplatin every three weeks. Standard dosages of paclitaxel and carboplatin were delivered to patients with escalating dosages of REOLYSIN(R) intravenously. The second component of the trial includes the enrolment of a further 12 patients at the maximum dosage of REOLYSIN(R) in combination with a standard dosage of paclitaxel and carboplatin.

Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours such as head and neck, melanoma, lung and ovarian cancers that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists. The primary objective of the trial is to determine the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), recommended dose and dosing schedule and safety profile of REOLYSIN(R) when administered in combination with paclitaxel and carboplatin. Secondary objectives include the evaluation of immune response to the drug combination, the body's response to the drug combination compared to chemotherapy alone and any evidence of anti-tumour activity.

Collaborations - Results

On April 15, 2008, we announced that a poster presentation by Dr. Anders Kolb of the Nemours Center for Childhood Cancer Research entitled "Radiation in Combination with Reolysin for Pediatric Sarcomas" was presented at the American Association for Cancer Research ("AACR") Annual Meeting. The poster covers preclinical work using reovirus in combination with radiation in mice implanted with pediatric rhabdomyosarcoma and Ewing's sarcoma tumours. The results demonstrated that the combination of reovirus and radiation significantly enhanced efficacy compared to either treatment alone in terms of tumour regression and event-free survival.

On April 15, 2008, we announced tha
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... According to Jeff Howell, Partner of Nidea ... new development in Downtown Toronto is expanding at a ... 755 storeys of new development last week (including three ... dominating the Toronto skyline for the foreseeable future in ... for new development. , As the Toronto city council ...
(Date:9/15/2014)... , Sept. 15, 2014 EnGeneIC, ... revolutionizing the treatment of cancer through the targeted ... announced that, together with the Asbestos Disease Research ... Institute New South Wales (NSW) Premier,s Award for ... recipients are the hospitals that will be involved ...
(Date:9/15/2014)... team of researchers led by Northeastern University has ... inter-nanotube junctions and a variety of nanocarbon structures ... and easily scalable, which will allow the researchers ... for use in applications ranging from electronic devices ... cars to sports equipment. , Their findings were ...
(Date:9/15/2014)... -- The chemistry, taste, and health effects of tea can ... by the nonprofit American Botanical Council (ABC). Recent research by ... effects on the phytochemical compounds in tea ( Camellia sinensis ... Ahmed in the Yunnan province of ... the future of medicinal botanicals. Dr. Ahmed,s report ...
Breaking Biology Technology:ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 2EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 3Northeastern University Researchers Develop Novel Method for Working with Nanotubes 2Tea Taste and Quality Affected by Climate Change 2Tea Taste and Quality Affected by Climate Change 3Tea Taste and Quality Affected by Climate Change 4
... 28 Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ) will ... on Wednesday, September 3, 2008 at 9:10 a.m. ET, ... September 4,2008 at 11:30 a.m. ET, and at the ... Tuesday, September 9, 2008 at 10:55,a.m. ET. Mark G. ...
... ViroPharma Incorporated,(Nasdaq: VPHM ) today announced that ... will present at the Thomas Weisel Partners,2008 Healthcare ... 4, 2008.,The conference is being held at the ... also announced that William Roberts, vice president,corporate communications ...
... 28 ThromboGenics NV,(Euronext Brussels: THR), a biotechnology ... disease and cancer, is today issuing a,business update ... period ending,June 30, 2008., During the first ... of,key milestones which have positioned the Company to ...
Cached Biology Technology:Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences 2ViroPharma to Present at Three September Healthcare Conferences 2ThromboGenics Announces Half Year Results 2008 2ThromboGenics Announces Half Year Results 2008 3ThromboGenics Announces Half Year Results 2008 4ThromboGenics Announces Half Year Results 2008 5
(Date:9/16/2014)... Keystone XL pipeline (KXL) would likely increase oil sands ... surveyed by the non-profit organization Near Zero. The results ... Impact," and includes both supporters and opponents of the ... sands could lead to significantly higher greenhouse gas emissions, ... respond. , "This report examines three main scenarios ...
(Date:9/16/2014)... Southeast Alaska to the white sand beaches of Florida,s ... towns, coastal residents around the U.S. share a common ... lines. That,s a primary finding of a new study ... in the journal Society & Natural Resources . ... place to place to place. Each environment is different ...
(Date:9/16/2014)... 16, 2014  Valencell, Inc., a leader in performance ... of 18 "Showcase Companies" representing North Carolina,s ... CED Tech Venture Conference on September 16-17 th ... in Raleigh, North Carolina . Valencell,s ... discussion during the "Digital Health Spotlight Sector" on how ...
Breaking Biology News(10 mins):Keystone XL would likely raise oil sands production and greenhouse gas emissions 2Politics divide coastal residents' views of environment, UNH research finds 2Politics divide coastal residents' views of environment, UNH research finds 3Valencell, Inc. Selected as 'Showcase Company' at CED Tech Venture Conference 2014 2
... have found how two molecules fight in the blood to ... a large protein, which forms a protective shield around cancer ... by a small protein that exists in the blood. ... cancer, infected cells lose growth control and eventually form tumours ...
... prevented the onset of type 1 diabetes in mice ... a receptor on the surface of immune T-cells. According ... in the January issue of the journal Diabetes, have ... , More than 700,000 Americans have type 1 ...
... An immuno-contraceptive vaccine causes an animal's immune system to ... structure in the reproductive process. The antibodies can act ... fertilization or the production of sperm and ova. ... tested nearly 20 years ago, regard it as more ...
Cached Biology News:Scientists discover how body fights to control spread of cancer 2Antibody therapy prevents type 1 diabetes in mice 2Manipulating nature: Scientists query wildlife birth-control method 2
UV LAMP 300 NM 8W T5, 1 EA. Category: Nucleid Acid Detection Systems....
... The SelectFX Alexa Fluor 488 Cytochrome ... reagents you need to detect cytochrome c ... anti-cytochrome c primary antibody and an ... Fluor 488 dye exhibits bright green fluorescence ...
Kit for Detection of Mitochondrial Membrane Potential...
MOUSE ANTI NEUROFILAMENTS 140+160 KD...
Biology Products: